Global Rifabutin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rifabutin Market Research Report 2024
Highlights
The global Rifabutin market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2034, witnessing a CAGR of % during the forecast period 2024-2034. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rifabutin is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
Asia-Pacific market for Rifabutin is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The global market for Rifabutin in Pharmacy is estimated to increase from $ million in 2023 to $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The key global companies of Rifabutin include RedHill Biopharma Ltd., Pfizer, Lupin, Olon, Janssen Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., NOVITIUM PHARMA, Guangzhou Tosun Pharmaceutical and Chongqing Huapont Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rifabutin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rifabutin.
The Rifabutin market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2018 to 2034. This report segments the global Rifabutin market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rifabutin companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
RedHill Biopharma Ltd.
Pfizer
Lupin
Olon
Janssen Pharma
JINLAN Pharm-Drugs Technology Co., Ltd.
NOVITIUM PHARMA
Guangzhou Tosun Pharmaceutical
Chongqing Huapont Pharmaceutical
5M Biotech India
SR Chemical And Pharmaceuticals
LOK-BETA Pharmaceuticals (I) Pvt Ltd
HANGZHOU HEXO CHEMTECH CO., LTD
Segment by Type
25 mg
100 mg
150 mg
Pharmacy
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Rifabutin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12The main points and conclusions of the report.
The global Rifabutin market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2034, witnessing a CAGR of % during the forecast period 2024-2034. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rifabutin is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
Asia-Pacific market for Rifabutin is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The global market for Rifabutin in Pharmacy is estimated to increase from $ million in 2023 to $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The key global companies of Rifabutin include RedHill Biopharma Ltd., Pfizer, Lupin, Olon, Janssen Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., NOVITIUM PHARMA, Guangzhou Tosun Pharmaceutical and Chongqing Huapont Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rifabutin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rifabutin.
The Rifabutin market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2018 to 2034. This report segments the global Rifabutin market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rifabutin companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
RedHill Biopharma Ltd.
Pfizer
Lupin
Olon
Janssen Pharma
JINLAN Pharm-Drugs Technology Co., Ltd.
NOVITIUM PHARMA
Guangzhou Tosun Pharmaceutical
Chongqing Huapont Pharmaceutical
5M Biotech India
SR Chemical And Pharmaceuticals
LOK-BETA Pharmaceuticals (I) Pvt Ltd
HANGZHOU HEXO CHEMTECH CO., LTD
Segment by Type
25 mg
100 mg
150 mg
Segment by Application
Pharmacy
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Rifabutin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12The main points and conclusions of the report.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices